A mechanism-informed secondary pharmacology panel designed to generate compound-specific evidence for carcinogenic risk assessment within an integrated Weight of Evidence strategy.
Learn which pharmaceuticals may require carcinogenicity studies, what ICH S1B(R1) changed, and how secondary pharmacology contributes to an integrated Weight of Evidence assessment.
ICEADR™ comprises 39 targets and 68 functional assays selected to evaluate pharmacological activities with potential relevance to carcinogenic risk. The panel supports assessment of both parent compounds and major metabolites and is designed with reference to the ICH S1B(R1) Weight of Evidence framework.
Targets selected across multiple biological mechanisms associated with potential carcinogenic liability.
Functional formats designed to characterize activation, inhibition, agonism, antagonism, or pathway-level effects.
Available as either single-concentration screening or concentration–response characterization.
ICH S1B(R1) identifies secondary pharmacology data for the parent compound and major human metabolites as one of the principal evidence streams used to inform compound selectivity, off-target potential, and carcinogenic risk. ICEADR™ is designed to support this evidence-generation need through focused functional assessment of targets with mechanistic relevance to carcinogenesis.
The panel places particular emphasis on nuclear receptors, GPCRs, and enzyme targets, while extending coverage to additional pathways associated with epigenetic regulation, inflammation, immune modulation, cellular injury, and genotoxic stress.
Functional assessment of receptor systems associated with hormonal regulation, steroid signaling, metabolic control, and proliferative responses.
Evaluation of receptor-mediated pathways relevant to endocrine balance, immune signaling, tissue responses, and long-term pharmacological modulation.
Functional testing of enzymes associated with epigenetic regulation, inflammatory pathways, immune responses, cellular injury, and genotoxic mechanisms.
ICEADR™ extends beyond a general-purpose safety panel by including targets linked to multiple biological mechanisms that may contribute to carcinogenic risk.
The platform supports both efficient primary screening and detailed quantitative characterization of confirmed pharmacological activity.
Efficiently profile compounds across the selected panel to identify potential activities that may warrant confirmation and mechanistic follow-up.
Quantitatively characterize potency, concentration dependence, and functional direction to support exposure-based interpretation and follow-up decisions.
Kinase assays are performed using a 1 mM ATP testing condition to provide functional evaluation under an ATP concentration intended to better represent a physiologically relevant biochemical environment.
A selective parent compound may not fully represent the pharmacological profile of a clinically relevant metabolite. ICEADR™ enables the same functional assessment strategy to be applied to both the parent compound and selected metabolites, supporting a more complete evaluation of potential off-target activity.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
